SCHEDULE: Balyasny Asset Management Discloses Crescent Biopharma Stake

Balyasny Asset Management L.P. and affiliated entities have reported beneficial ownership of 5.48% of Crescent Biopharma, Inc. common stock as of March 31, 2026.

Summary

• Balyasny Asset Management L.P. (BAM), along with its general partner BAM GP LLC, holding company Balyasny Asset Management Holdings LP, general partner Dames GP LLC, and Dmitry Balyasny, have collectively disclosed beneficial ownership of Crescent Biopharma, Inc. common stock.
• The total number of shares beneficially owned by the reporting persons is 1,510,033.
• This represents approximately 5.48% of the class of securities outstanding.
• The reporting persons have sole voting power and sole dispositive power over these shares.
• The filing indicates that the shares were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, indicating institutional interest without providing specific performance data.

Positives

• Balyasny Asset Management's investment indicates confidence in Crescent Biopharma, potentially signaling positive future prospects.
• The reporting persons hold sole voting and dispositive power, suggesting a clear investment strategy and control over their stake.

Negatives

• The filing does not contain any negative financial or operational information about Crescent Biopharma itself, as it is a Schedule 13G filing focused on ownership.

Risks

• As with any investment, there is a risk of market fluctuations affecting the value of Crescent Biopharma's stock.
• The reporting persons' investment strategy could change, leading to a sale of shares and potential downward pressure on the stock price.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from Crescent Biopharma. It is a disclosure of beneficial ownership by an investment management firm.

Industry Context

StockSavvy.ai notes that significant stake disclosures by institutional investors like Balyasny Asset Management often signal a belief in the company's underlying value or future growth potential within the biopharmaceutical sector.

Stakeholder Impact

• Shareholders may view the increased institutional ownership as a positive sign, potentially increasing demand for the stock.
• The investment by Balyasny Asset Management could influence future corporate strategy or governance decisions if their stake grows or if they engage with management.

Next Steps

• Balyasny Asset Management will continue to hold or manage its stake in Crescent Biopharma.
• Crescent Biopharma will continue its operations and report its financial and operational results in subsequent filings.

Key Dates

Recommendation

This filing is a disclosure of beneficial ownership and does not contain sufficient operational or financial performance data to warrant a buy or sell recommendation. It indicates institutional interest, suggesting a 'hold' is appropriate pending further company-specific news or financial reports.

Keywords

Crescent Biopharma, Balyasny Asset Management, Schedule 13G, Beneficial Ownership, Common Stock, Investment Management, SEC Filing, Institutional Investor